People with type 2 diabetes often struggle to keep their blood sugar in a safe range. Many rely on HbA1c tests, but these do not show day-to-day fluctuations. This research offers new insights using continuous glucose monitoring to guide better management. The study matters for anyone taking metformin who needs additional medication to control their glucose levels. It compares four common add-on treatments to see which helps patients stay in a healthy range more often.
Researchers enrolled 1,080 participants with type 2 diabetes who were already taking metformin. Each person received one of four glucose-lowering medications added to their current regimen. The four options were insulin glargine, glimepiride, liraglutide, or sitagliptin. Participants continued taking their assigned drug for five years, with an average follow-up of five plus or minus 1.3 years. The study tracked how often blood sugar stayed within the target range of 70 to 180 milligrams per deciliter. It also measured time spent below 70 mg/dL, which indicates low blood sugar or hypoglycemia.
The results showed clear differences between the drug groups. Sitagliptin and liraglutide produced the highest percentage of time spent in the target range. They also resulted in the lowest amount of time spent below 70 mg/dL and the lowest variability in glucose levels. In contrast, the glimepiride group had the lowest time in range and the highest variability. This group also experienced the most hypoglycemic events measured by the monitor. Insulin glargine and glimepiride showed higher variability and lower time in range compared to the other drugs when grouped by HbA1c levels.
Safety was a major focus of the trial. The number of hypoglycemic events was significantly higher in the glimepiride group compared to sitagliptin and liraglutide. Insulin glargine and glimepiride also showed higher rates of low blood sugar within each HbA1c stratum. The study did not report serious adverse events or discontinuations due to side effects. Mean glucose levels did not differ among the treatments when adjusted for HbA1c. This suggests the drugs worked similarly to lower average sugar, but differed in how stable the levels remained.
This single study provides important clinical insights but should not be viewed as the final word. It is an RCT comparing treatment effects among four groups, which gives strong evidence for these specific comparisons. However, the study was conducted in a specific setting and may not reflect every patient experience. People should not overreact to this single trial. Individual health needs vary, and doctors must consider all factors before changing a treatment plan. The consensus goals of very low time below range and high time in range were best achieved with sitagliptin and liraglutide. These findings support using these options when stability is a priority.
For patients right now, this research highlights the value of looking beyond HbA1c. CGM metrics provide a fuller picture of daily life with diabetes. If you are on metformin and considering an add-on, these results suggest sitagliptin or liraglutide may offer better stability and safety. Always discuss these options with your healthcare provider to find the best fit for your specific situation.